In March, we added 106 citations in DIDB, including 50 in vitro (with 15 articles published in March 2025) and 56 in vivo articles (with 30 articles published in March 2025).
2 NDA/BLAs approved in 2025, including datopotamab deruxtecan (DATROWAY) and suzetrigine (JOURNEAVX), were also curated in DIDB.
You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.
As always, feel free to contact us if you have any questions or comments.